Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.

Burke BP, Levin BR, Zhang J, Sahakyan A, Boyer J, Carroll MV, Colón JC, Keech N, Rezek V, Bristol G, Eggers E, Cortado R, Boyd MP, Impey H, Shimizu S, Lowe EL, Ringpis GE, Kim SG, Vatakis DN, Breton LR, Bartlett JS, Chen IS, Kitchen SG, An DS, Symonds GP.

Mol Ther Nucleic Acids. 2015 Apr 14;4:e236. doi: 10.1038/mtna.2015.10.

2.

Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression.

Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA.

Mol Ther. 2013 May;21(5):1055-63. doi: 10.1038/mt.2013.28. Epub 2013 Mar 12.

3.

Using the BLT humanized mouse as a stem cell based gene therapy tumor model.

Vatakis DN, Bristol GC, Kim SG, Levin B, Liu W, Radu CG, Kitchen SG, Zack JA.

J Vis Exp. 2012 Dec 18;(70):e4181. doi: 10.3791/4181.

4.

In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.

Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sandoval C, Balamurugan A, Yang OO, Zack JA.

PLoS Pathog. 2012;8(4):e1002649. doi: 10.1371/journal.ppat.1002649. Epub 2012 Apr 12.

5.

Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication.

Dadachova E, Kitchen SG, Bristol G, Baldwin GC, Revskaya E, Empig C, Thornton GB, Gorny MK, Zolla-Pazner S, Casadevall A.

PLoS One. 2012;7(3):e31866. doi: 10.1371/journal.pone.0031866. Epub 2012 Mar 9. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/c4cb1c2c-a436-4f7a-ada9-1feb42aebca1.

6.

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):E1408-16. doi: 10.1073/pnas.1115050108. Epub 2011 Nov 28.

7.

HIV latency in the humanized BLT mouse.

Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, Cortado R, Bristol G, An DS, Zack JA.

J Virol. 2012 Jan;86(1):339-47. doi: 10.1128/JVI.06366-11. Epub 2011 Nov 9.

8.

A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N, Kittipongdaja P, Chen A, Bristol G, Galic Z, Zack JA, Yang O, Chen IS, Lee B, An DS.

Blood. 2010 Feb 25;115(8):1534-44. doi: 10.1182/blood-2009-04-215855. Epub 2009 Dec 17.

9.

Differentially stimulated CD4+ T cells display altered human immunodeficiency virus infection kinetics: implications for the efficacy of antiviral agents.

Vatakis DN, Nixon CC, Bristol G, Zack JA.

J Virol. 2009 Apr;83(7):3374-8. doi: 10.1128/JVI.02161-08. Epub 2009 Jan 7.

10.

Generation of T lineage cells from human embryonic stem cells in a feeder free system.

Galić Z, Kitchen SG, Subramanian A, Bristol G, Marsden MD, Balamurugan A, Kacena A, Yang O, Zack JA.

Stem Cells. 2009 Jan;27(1):100-7. doi: 10.1634/stemcells.2008-0813.

11.

Viral complementation allows HIV-1 replication without integration.

Gelderblom HC, Vatakis DN, Burke SA, Lawrie SD, Bristol GC, Levy DN.

Retrovirology. 2008 Jul 9;5:60. doi: 10.1186/1742-4690-5-60.

12.

Primary cell model for activation-inducible human immunodeficiency virus.

Burke B, Brown HJ, Marsden MD, Bristol G, Vatakis DN, Zack JA.

J Virol. 2007 Jul;81(14):7424-34. Epub 2007 May 2.

13.

Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells.

Vatakis DN, Bristol G, Wilkinson TA, Chow SA, Zack JA.

J Virol. 2007 Apr;81(7):3574-82. Epub 2007 Jan 17.

14.

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.

Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, Chorn N, Lin LS, Bristol G, Boyd MP, MacPherson JL, Fanning GC, Todd AV, Ely JA, Zack JA, Symonds GP.

Hum Gene Ther. 2004 Mar;15(3):251-62.

PMID:
15018734
15.

Molecular characterization, reactivation, and depletion of latent HIV.

Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, Kitchen CM, Berger EA, Zack JA.

Immunity. 2003 Sep;19(3):413-23.

16.

Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1.

Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, Zack JA, Waring AJ, Yang OO, Lehrer RI.

Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1813-8.

17.

Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.

Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, Bell JE, Bannert N, Crawford K, Wang H, Schols D, De Clercq E, Kunstman K, Wolinsky SM, Gabuzda D.

J Virol. 2001 Nov;75(21):10073-89.

18.

Antibody-directed targeting of retroviral vectors via cell surface antigens.

Morizono K, Bristol G, Xie YM, Kung SK, Chen IS.

J Virol. 2001 Sep;75(17):8016-20.

19.

Effect of cytokines on HIV-induced depletion of thymocytes in vivo.

Uittenbogaart CH, Boscardin WJ, Anisman-Posner DJ, Koka PS, Bristol G, Zack JA.

AIDS. 2000 Jul 7;14(10):1317-25.

PMID:
10930145
20.

Thymic dendritic cells are primary targets for the oncogenic virus SL3-3.

Uittenbogaart CH, Law W, Leenen PJ, Bristol G, van Ewijk W, Hays EF.

J Virol. 1998 Dec;72(12):10118-25.

21.

Regions of human immunodeficiency virus type 1 nef required for function in vivo.

Aldrovandi GM, Gao L, Bristol G, Zack JA.

J Virol. 1998 Sep;72(9):7032-9.

22.

Human immunodeficiency virus inhibits multilineage hematopoiesis in vivo.

Koka PS, Fraser JK, Bryson Y, Bristol GC, Aldrovandi GM, Daar ES, Zack JA.

J Virol. 1998 Jun;72(6):5121-7.

23.

Isolation of mycobacterium-reactive CD1-restricted T cells from patients with human immunodeficiency virus infection.

Gong J, Stenger S, Zack JA, Jones BE, Bristol GC, Modlin RL, Morrissey PJ, Barnes PF.

J Clin Invest. 1998 Jan 15;101(2):383-9.

24.

Preparation and maintenance of SCID-hu mice for HIV research.

Bristol GC, Gao LY, Zack JA.

Methods. 1997 Aug;12(4):343-7.

PMID:
9245615
25.

High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells.

An DS, Koyanagi Y, Zhao JQ, Akkina R, Bristol G, Yamamoto N, Zack JA, Chen IS.

J Virol. 1997 Feb;71(2):1397-404.

26.

Organization of the V gene segments in mouse T-cell antigen receptor alpha/delta locus.

Wang K, Klotz JL, Kiser G, Bristol G, Hays E, Lai E, Gese E, Kronenberg M, Hood L.

Genomics. 1994 Apr;20(3):419-28.

PMID:
8034314
29.

Simplified reading and storage of DNA sequence data.

Andersen RD, Bristol G.

Am Biotechnol Lab. 1991 May;9(4):26. No abstract available.

PMID:
1367203
30.

Mechanisms of thymic lymphomagenesis by the retrovirus SL3-3.

Hays EF, Bristol G, McDougall S.

Cancer Res. 1990 Sep 1;50(17 Suppl):5631S-5635S.

31.

Progression to development of lymphoma in the thymus of AKR mice treated neonatally with SL 3-3 virus.

Hays EF, Bristol GC, Lugo JP, Wang XF.

Exp Hematol. 1989 Dec;17(11):1116-21.

PMID:
2511036
32.

Development of lymphoma in the thymus of AKR mice treated with the lymphomagenic virus SL 3-3.

Hays EF, Bristol GC, McDougall S, Klotz JL, Kronenberg M.

Cancer Res. 1989 Aug 1;49(15):4225-30.

33.

Metal-dependent binding of a factor in vivo to the metal-responsive elements of the metallothionein 1 gene promoter.

Andersen RD, Taplitz SJ, Wong S, Bristol G, Larkin B, Herschman HR.

Mol Cell Biol. 1987 Oct;7(10):3574-81.

34.

Rat metallothionein multigene family.

Andersen RD, Taplitz SJ, Birren BW, Bristol G, Herschman HR.

Experientia Suppl. 1987;52:373-84. Review.

PMID:
2959527
35.
36.

Effect of parathyroid hormone on osmotic fragility of human erythrocytes.

Bogin E, Massry SG, Levi J, Djaldeti M, Bristol G, Smith J.

J Clin Invest. 1982 Apr;69(4):1017-25.

Supplemental Content

Loading ...
Support Center